Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Solventum Corporation (SOLV) Presents at Stifel 2025 Healthcare Conference Transcript
Solventum Corporation ( SOLV ) Stifel 2025 Healthcare Conference November 12, 2025 11:20 AM EST Company Participants Wayde McMillan - Chief Financial Officer Doug Bartlett Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Frederick Wise Stifel, Nicolaus & Company, Incorporated, Research Division Luckily, Wayde is not the Chief Executive Officer. He tells me, I'm not sure.
SOLV vs. DHR: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Solventum (SOLV) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
Solventum (SOLV) Upgraded to Strong Buy: What Does It Mean for the Stock?
Solventum (SOLV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SOLV or DHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
SOLV Gains on Q3 Earnings & Sales Beat, Raises '25 EPS Outlook
Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.
Solventum Corporation (SOLV) Q3 2025 Earnings Call Transcript
Solventum Corporation ( SOLV ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan Hanson - CEO & Director Wayde McMillan - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Jason Bednar - Piper Sandler & Co., Research Division Travis Steed - BofA Securities, Research Division Lei Huang - Wells Fargo Securities, LLC, Research Division Presentation Operator Good afternoon. My name is Regina, and I will be your conference operator today.
Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Solventum (SOLV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Solventum (SOLV) Surpasses Q3 Earnings and Revenue Estimates
Solventum (SOLV) came out with quarterly earnings of $1.5 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.64 per share a year ago.
Unveiling Solventum (SOLV) Q3 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Solventum (SOLV) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?
Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.
Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
